Featured Video Play Icon

Tiefenbacher Pharmaceuticals: Thanks for visiting us at CPhI 2022 in Frankfurt!

Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group:

CPhI 2022, the world`s leading pharma event, has just come to an end. It was wonderful to meet our valued customers and partners in person again. Our experts enjoyed three very successful days full of exciting meetings and inspiring discussions. It was a great pleasure to present TIEFENBACHER GROUP´s latest ideas to make pharmaceuticals more affordable, more available, and better than before.  

Thanks a lot for visiting us at our new booth representing TIEFENBACHER GROUP as a global health pioneer. We are already looking forward to seeing you next year in Barcelona at CPhI 2023!

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


Featured Video Play Icon

TIEFENBACHER GROUP opens new manufacturing site in Cyprus /Europe

Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group

Did you know that TIEFENBACHER GROUP heavily invests in its in-house production capacities for high-quality pharmaceuticals? We are excited to announce that our new manufacturing site in Cyprus was ceremoniously opened in mid-October. The “Delorbis” plant is one of the most modern pharmaceutical production site in the European Union. Its facilities are equipped with state-of-the art technologies for the manufacturing of oral dosage forms. This investment follows TIEFENBACHER GROUP´s strategy to strengthen its position as a global, fully integrated pharmaceutical company.

Check out our short video and get an impression of the festive inauguration of the new plant!

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®

TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and flexible dosing.

TIEFENBACHER GROUP and OnDosis today announced the launch of the OYSTA® brand. OYSTA® represents the extensive co-development portfolio of drug/device combinations that was initiated in September 2020 and covers several indications such as ADHD, Parkinson´s disease, transplantation, and pain medicines as well as rare pulmonary diseases. The first product, combining a stimulant with the proprietary dosage manager for patients with ADHD, is already planned for launch in the US in 2024. Other indications will stand in line as next wave developments.

OYSTA® captures the essence of the value proposition of the products under development: a safe “shell” (proprietary dosage manager) to protect medicines formulated as “pearls” (pellets or granules) to allow for intuitive, flexible, and precise dosing.

Through the OYSTA® collaboration, OnDosis will benefit from a partner with leading competence in pharmaceutical development, supply chain, and B2B commercialization, whilst TIEFENBACHER GROUP gets access to an innovative product concept with game-changing potential in the new era of individualization of treatments and digitalization in healthcare.

“OYSTA® allows us to clearly position the products we are co-developing in conversation with commercialization partners as well as with health care professionals and end users. It is ultimately a sign that our common efforts to bring innovation to patients is getting closer to market” says Kristian Ruepp, Managing Director at TIEFENBACHER GROUP.

“OYSTA® perfectly captures the essence of what we want to achieve together in this exciting collaboration: individualized dosing of solid oral medicines formulated as “pearls” and protected within a device “shell” which gives reassurance to patients, caregivers, and healthcare professionals.  Under one name, we are co-developing a portfolio of innovative products as one team, with the ambition to revolutionize how patients take their medicines. That revolution is now accelerating” says Martin Olovsson, CEO at OnDosis.

TIEFENBACHER GROUP and OnDosis will first present the OYSTA® brand in public at CPhI 2022 in Frankfurt (Nov 1-3). To schedule a meeting please contact TIEFENBACHER GROUP via info@aet.eu.

For any request regarding a collaboration in one of the five indications mentioned above, please contact TIEFENBACHER GROUP. For interest in any other indication or solely the device please contact OnDosis:

Dr. Kristian Ruepp
Joint Managing Director, TIEFENBACHER GROUP

Tel: +49 40 – 44 18 09-0; info@aet.eu

Martin Olovsson
CEO, OnDosis

Tel: +46 76 772 85 01; m.olovsson@ondosis.com

OYSTA® is a registered trademark jointly owned by TIEFENBACHER GROUP and OnDosis. The OYSTA® products are co-developed based in the proprietary dosage manager device platform developed by OnDosis.

About Tiefenbacher Group – Pioneering Healthcare since 1963

100% family owned since 1963 TIEFENBACHER GROUP is a global health care company providing innovative and best-in-class solutions along the entire pharmaceutical value chain. That includes the distribution of API ́s and the development, manufacturing, and registration of finished dosage forms. The world ́s most trusted health care brands count on TIEFENBACHER’s pioneer spirit as well as its pharmaceutical excellence. Leveraging its global presence including own laboratories and manufacturing sites, TIEFENBACHER is driven to make pharmaceuticals more affordable, more available, and better than before. There is one purpose driving TIEFENBACHER’s about 800 employees day by day: improving the life of millions of patients worldwide. www.tiefenbachergroup.com

About OnDosis

A Swedish Life science company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage — individualized, intuitive, and intelligent — in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies. By combining traditional drug-based treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve. www.ondosis.com


TIEFENBACHER PHARMACEUTICALS New market launch: Anticoagulant medicine Apicaban

TIEFENBACHER PHARMACEUTICALS New market launch: Anticoagulant medicine Apixaban

New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the anticoagulant medicine Apixaban in Canada

We at TIEFEENBACHER PHARMACEUTICALS are driven by enabling people around the world a better access to more affordable high-quality medicines. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Apixaban for an early market entry in Canada.
Apixaban is an oral anticoagulant (blood thinner) indicated for the prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with atrial fibrillation, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of their recurrence. 2,5 mg and 5 mg tablets have been developed in TIEFENBACHER GROUP’s own laboratories in India and will be marketed in Canada by our cooperation partner, one of the biggest generic pharmaceuticals in the world.
A generic launch in further international markets will follow. With this early market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


Meet TIEFENBACHER PHARMACEUTICALS at CPHI 2022 in Frankfurt /Germany

Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group: Meet us at CPHI in Frankfurt!

We are very excited to meet our valued customers and partners once again on CPHI 2022, the world’s leading pharma industry event!

Explore our new booth representing Tiefenbacher Group as a global pioneer and discover our latest portfolio and innovations in the field of raw materials, finished dosage forms, and medical devices! Get in touch with our experts to discuss new business opportunities and ideas for improving the life of patients worldwide.

CPHI 2022 will take place on November 1-3 at Messe Frankfurt, Germany. We’ll be happy to meet you at our stand 80B70 at any time during the event. The arrangement of prescheduled meetings is highly appreciated. Please contact our team to request a meeting or send a meeting request to cphi@aet.eu.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


Meet TIEFENBACHER PHARMACEUTICALS at BePharma in Mexico City 2022 from October 10-12!

Reach out to AET – TIEFENBACHER PHARMACEUTICALS at BePharma, the most important Pharma B2B Event in Latin America from October 10-12!

Discover our latest product portfolio in Mexico City and find out how we strive to make pharmaceuticals more affordable, more available, and better than before!

 

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms (FDF) and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


TIEFENBACHER PHARMACEUTICALS New market launch: generic version of diabetis medicine Vildagliptin/ Metformin in Africa

TIEFENBACHER PHARMACEUTICALS New market launch: Diabetis medicine Vildagliptin / Metformin

NEW Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the diabetes medicine Vildagliptin and Vildagliptin /Metformin in Africa

We at Tiefenbacher Pharmaceuticals strive to make our high-quality medicines available and affordable to as many people as possible around the world. Therefore Tiefenbacher Group is happy to share that we have successfully prepared the launch of the generic version of Vildagliptin and the combination product Vildagliptin/Metformin in Africa.

Generally, Vildagliptin and Vildagliptin/Metformin are diabetes medicines that are used to control the blood glucose (sugar) in adults with type 2 diabetes. The tablets are marketed in South Africa (Vildagliptin 50 mg) and Namibia (Vildagliptin/Metformin 50/1000 mg) by our marketing partner, a well-known South African based pharmaceutical company.

We develop the products in our own laboratories in Hyderabad, India. Afterwards they will be marketed in Europe and further international countries as soon as the patents of the originator products have expired.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com


Tiefenbacher: Employee benefits and climate reduction goals

Environmentally friendly and health-promoting: TIEFENBACHER GROUP offers bike leasing to employees

Employees benefits while reducing our impact on the environment with climate reduction goals – we take action on many fronts.
From racing bikes to E-bikes: since this year all our employees at our Hamburg headquarters can choose from a broad range of company bikes to lease. A great opportunity for everyone to stay fit and healthy and fully aligned with TIEFENBACHER GROUP´s strategy of doing business sustainable! As with car leasing, the monthly instalment is deducted from the monthly gross salary through salary conversion.

We are very optimistic to reach soon our target that at least 30% of our Hamburg employees will cycle to work instead of taking their car. One step further on our way to less CO2 emissions!  And of course, we have sufficient bicycle parking spaces in our underground garage – including numerous electric charging station for electric vehicles.

For further information about our corporate social responsibility activities and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com

 

About Tiefenbacher Group – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


Tiefenbacher Pharmaceuticals launch Rivaroxaban

TIEFENBACHER PHARMACEUTICALS Global market launch: Anticoagulant medicine Rivaroxaban

Tiefenbacher Pharmaceuticals launch Rivaroxaban

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be available for all patients around the world – irrespective of their origin or nationality. That´s why Tiefenbacher Pharmaceuticals is happy to share that we have successfully expanded the launch of the generic version of Rivaroxaban to Central America, the Caribbean and Kazakhstan.

Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. The tablets are marketed in the strengths 10 mg, 15 mg, and 20 mg by our cooperation partner, one of the biggest generic pharmaceutical companies in the world. The product has been developed in TIEFENBACHER GROUP´s own laboratories in Hyderabad, India, and has already been launched in certain patent-free European markets before. A launch in further international countries like Thailand, Albania, Serbia, Peru, Chile, and North Macedonia will follow soon. Overall, our country scope covers about 80 countries around the world. With this global market entry, we enable millions of patients worldwide access to a life- improving, high-quality treatment – also in emerging countries where GMP-compliance is not always a standard yet.

We will keep you updated about launches of this and other products in further international markets.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com


TIEFENBACHER PHARMACEUTICALS New market launch: TERIFLUNOMIDE

TIEFENBACHER PHARMACEUTICALS New market launch: TERIFLUNOMIDE

New market launch: TIEFENBACHER PHARMACEUTICALS successfully launches first generic version of the Multiple Sclerosis (MS) medicine Teriflunomide in Canda

We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why Tiefenbacher Pharmaceuticals is happy to share that we have successfully prepared the launch of the generic version of Teriflunomide for a market entry on day one after patent expiration in Canada.

Teriflunomide is used to improve the life of patients suffering from Multiple Sclerosis (MS) – a chronic disease that effects the central nervous system. The 14 mg film coated tablets are developed and produced in TIEFENBACHER GROUPs own site in India and will be marketed in Canada by our partners, two well-known generic pharmaceutical companies. Our product has already been launched in time in Australia before – a launch in further international markets will follow as soon as the patents of the originator product expire. With this generic market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com